Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (rod photoreceptor cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: phloroglucinol, dronedarone hydrochloride, amlodipine besylate +38 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 2837
Sealed predictions
- CACNA1F in dopamine neurons, braak-0.20 (p 0.602) → -0.05 (p 0.893)receipt 2844
Swarm cases
receipt 2844: CACNA1F in dopamine neurons, braak
- power
- full sample -0.18 (p 0.471, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.14 (p 0.579, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.29 (p 0.239, n 18). could be the mix.
- skeptic
- leave-one-out range -0.29 to -0.07, sign flips 0; without severely affected donors -0.18 (p 0.471, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CACNA1F in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts